Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

883 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
Nozza S, Galli L, Antinori A, Chiappetta S, Mazzotta F, Zaccarelli M, Ottou S, De Battista D, Pogliaghi M, Di Pietro M, Malnati M, Ripa M, Bonora S, Lazzarin A; VEMAN Study Group. Nozza S, et al. Among authors: lazzarin a. Clin Microbiol Infect. 2015 May;21(5):510.e1-9. doi: 10.1016/j.cmi.2014.12.006. Epub 2014 Dec 11. Clin Microbiol Infect. 2015. PMID: 25656621 Free article. Clinical Trial.
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort.
d'Arminio Monforte A, Tavelli A, Cozzi-Lepri A, Castagna A, Passerini S, Francisci D, Saracino A, Maggiolo F, Lapadula G, Girardi E, Perno CF, Antinori A; Icona Foundation Study Group. d'Arminio Monforte A, et al. J Antimicrob Chemother. 2020 Mar 1;75(3):681-689. doi: 10.1093/jac/dkz512. J Antimicrob Chemother. 2020. PMID: 31865395
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study).
Nozza S, Ferrarese R, Poli A, Galli L, Sampaolo M, Bigoloni A, Galli A, Muccini C, Spagnuolo V, Lazzarin A, Clementi M, Mancini N, Castagna A. Nozza S, et al. Among authors: lazzarin a. J Antimicrob Chemother. 2020 Sep 1;75(9):2700-2702. doi: 10.1093/jac/dkaa231. J Antimicrob Chemother. 2020. PMID: 32542322 No abstract available.
Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
Tambussi G, Ghezzi S, Nozza S, Vallanti G, Magenta L, Guffanti M, Brambilla A, Vicenzi E, Carrera P, Racca S, Soldini L, Gianotti N, Murone M, Veglia F, Poli G, Lazzarin A. Tambussi G, et al. Among authors: lazzarin a. J Infect Dis. 2001 May 15;183(10):1476-84. doi: 10.1086/320188. Epub 2001 Apr 13. J Infect Dis. 2001. PMID: 11319683 Clinical Trial.
HIV-1 DNA and RNA kinetics in primary HIV infection.
Lillo F, Grasso M, Lodini S, Capiluppi B, Lazzarin A, Tambussi G. Lillo F, et al. Among authors: lazzarin a. J Biol Regul Homeost Agents. 2002 Jan-Mar;16(1):49-52. J Biol Regul Homeost Agents. 2002. PMID: 12003174
883 results